{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:21:27Z","timestamp":1764307287921,"version":"3.46.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Haploidentical hematopoietic stem cell transplantation (HID-HSCT) serves as an alternative treatment for severe aplastic anemia (SAA) patients lacking a suitable HLA-identical sibling donor. Compared to HLA-matched HSCT, HID-HSCT has higher rates of graft failure (GF) and graft-versus-host disease (GVHD). Recent studies suggest promising clinical outcomes when Mesenchymal stem cells (MSCs) are combined with HID-HSCT for SAA treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively analyzed clinical data from 190 SAA patients who underwent HID-HSCT with or without MSCs co-infusion. Patients were divided into two groups: the HID group (100 patients receiving only HID-HSCT) and the HID+MSC group (90 patients receiving HID-HSCT combined with MSC co-infusion).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis revealed that the HID+MSC group had a significantly higher 5-year overall survival rate compared to the HID group (86.6% vs. 75.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.036) and a significantly improved GRFS rate (76.6% vs. 64.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.048). While MSCs co-infusion did not significantly reduce the incidence of aGVHD or cGVHD, a downward trend was observed, particularly for cGVHD (16.6% vs. 26.0%). Both groups showed high cumulative engraftment rates for NE and PLT within 28 days post-transplant, with no significant differences. Regarding viral reactivation, EBV and CMV reactivation rates were similar between the two groups, though four patients in the HID group developed EBV-associated PTLD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates that combining HID-HSCT with MSCs co-infusion is a safe and effective therapeutic strategy that significantly improves survival rates and quality of life in SAA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1711958","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:15:32Z","timestamp":1764306932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Haploidentical transplantation combined with mesenchymal stem cells co-infusion improves survival in severe aplastic anemia: a single-center retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhengwei","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaoya","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3324\/haematol.2014.106096","article-title":"Outcome of aplastic anemia in adolescence: a survey of the severe aplastic Anemia working Party of the European Group for blood and marrow transplantation","volume":"99","author":"Dufour","year":"2014","journal-title":"Haematologica"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3324\/haematol.2014.109355","article-title":"First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy","volume":"99","author":"Yoshida","year":"2014","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00277-024-06152-6","article-title":"Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis","volume":"104","author":"Tan","year":"2025","journal-title":"Ann Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/bmt.2012.79","article-title":"A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia","volume":"47","author":"Xu","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/bmt.2016.347","article-title":"Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results","volume":"52","author":"Liu","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjh.14225","article-title":"Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.blre.2020.100772","article-title":"Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies","volume":"47","author":"Iftikhar","year":"2021","journal-title":"Blood Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"17986","DOI":"10.3390\/ijms140917986","article-title":"Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy","volume":"14","author":"Jin","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/TP.0b013e31825940a4","article-title":"The comparison of interleukin 6-associated immunosuppressive effects of human ESCs, fetal-type MSCs, and adult-type MSCs","volume":"94","author":"Chan","year":"2012","journal-title":"Transplantation"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.bbmt.2009.04.006","article-title":"A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD","volume":"15","author":"Guo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.blre.2005.11.002","article-title":"The role of mesenchymal stem cells in haemopoiesis","volume":"20","author":"Dazzi","year":"2006","journal-title":"Blood Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2040620720965411","DOI":"10.1177\/2040620720965411","article-title":"Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia","volume":"11","author":"Liu","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcyt.2021.09.014","article-title":"Infusion of haploidentical hematopoietic stem cells combined with mesenchymal stem cells for treatment of severe aplastic anemia in adult patients yields curative effects","volume":"24","author":"Ding","year":"2022","journal-title":"Cytotherapy"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/bmt.2013.224","article-title":"Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy","volume":"49","author":"Gao","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/bmt.2014.187","article-title":"Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","article-title":"Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Yu","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12015-010-9165-y","article-title":"Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord","volume":"7","author":"Majore","year":"2011","journal-title":"Stem Cell Rev Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1182\/blood.V98.8.2396","article-title":"Identification of mesenchymal stem\/progenitor cells in human first-trimester fetal blood, liver, and bone marrow","volume":"98","author":"Campagnoli","year":"2001","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s12015-023-10539-9","article-title":"Immunomodulatory mechanisms and therapeutic potential of mesenchymal stem cells","volume":"19","author":"Yang","year":"2023","journal-title":"Stem Cell Rev Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","article-title":"Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation","volume":"52","author":"Dotoli","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/cells8121577","article-title":"Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation \u2018MSC-FFM\u2019-outcome report of 92 patients","volume":"8","author":"Bonig","year":"2019","journal-title":"Cells"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","article-title":"Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial","volume":"10","author":"Huang","year":"2024","journal-title":"JAMA Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.scr.2013.10.001","article-title":"Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD","volume":"12","author":"Wu","year":"2014","journal-title":"Stem Cell Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/bmt.2013.154","article-title":"Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study","volume":"49","author":"Chen","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41409-024-02502-0","article-title":"Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"60","author":"Wang","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3324\/haematol.2024.286265","article-title":"Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation","volume":"110","author":"Pei","year":"2020","journal-title":"Haematologica"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1711958\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:15:32Z","timestamp":1764306932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1711958\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":35,"alternative-id":["10.3389\/fmed.2025.1711958"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1711958","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1711958"}}